Cullinan Oncology LLC

Cullinan Therapeutics and Taiho Pharmaceutical announced that the Phase 3 REZILIENT3 trial of zipalertinib plus platinum-based chemotherapy met its primary endpoint of progression-free survival in first-line treatment of locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations. The multicenter, randomized, controlled, open-label global trial enrolled 285 adults and demonstrated a statistically significant and clinically meaningful improvement in progression-free survival with manageable safety. The Independent Data Monitoring Committee recommended unblinding the study, and full results will be submitted for presentation at an upcoming international medical conference. Following the news, Cullinan Therapeutics shares rose 6.33% to $20.84 in after-hours trading, marking a new 52-week high.

Several biotech stocks reached 52-week highs on August 11, 2026, driven by quarterly reports and regulatory progress. Alamar Biosciences surged over 30% to $38.54 after reporting second-quarter revenue of $29.43 million and projecting full-year 2026 revenue between $116 million and $120 million. Dyne Therapeutics rose to $27.13 following FDA acceptance of its Biologics License Application for Z-Rostudirsen, with a decision expected in January 2027. Cullinan Therapeutics gained over 7% to $19.82 after narrowing its quarterly loss and announcing plans for Phase 2 trials in autoimmune diseases. Cardinal Health climbed to $258.30 on fiscal 2026 revenue of $254.2 billion and net earnings of $1.7 billion. DexCom reached $89.56 after reporting 13% second-quarter revenue growth to $1.31 billion and forecasting full-year revenue of $5.18 billion to $5.25 billion.